Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6775

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Beae9b9a D630 463b Ae93 F3da73c7049e 01)

Chemical structure of duloxetine hydrochloride, showing its molecular framework including a naphthalene ring, a thiophene ring, and the hydrochloride salt form. The diagram depicts the arrangement of atoms and bonds characteristic of duloxetine.*

FDA Label Image

Figure 1 (Beae9b9a D630 463b Ae93 F3da73c7049e 02)

A Kaplan-Meier estimator curve showing the proportion of patients with relapse over time (days) for Duloxetine versus placebo. The graph compares the relapse rates between Duloxetine and placebo treatments over approximately 200 days.*

FDA Label Image

Figure 2 (Beae9b9a D630 463b Ae93 F3da73c7049e 03)

A Kaplan-Meier survival curve graph comparing the proportion of patients with relapse over time in days from randomization. The graph has two lines: a solid line representing patients treated with duloxetine and a dashed line for those receiving placebo, showing relapse rates over approximately 275 days.*

FDA Label Image

Figure 1 (Beae9b9a D630 463b Ae93 F3da73c7049e 04)

A line graph showing the percentage of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. Four groups are compared: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and placebo. The graph illustrates differences in pain improvement across these treatments.*

FDA Label Image

Figure 2 (Beae9b9a D630 463b Ae93 F3da73c7049e 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The y-axis represents the percentage of patients improved, and the x-axis represents percent improvement in pain from baseline. The graph includes vertical marker lines at 30% and 50% improvement thresholds.*

FDA Label Image

Fig 5 (Beae9b9a D630 463b Ae93 F3da73c7049e 06)

A line graph showing the percentage of patients improved based on percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The y-axis represents the percentage of patients improved, and the x-axis shows increasing thresholds of pain improvement percentages from greater than 0% to 100%.*

FDA Label Image

Fig 6 (Beae9b9a D630 463b Ae93 F3da73c7049e 07)

This chart depicts the percentage of patients improved relative to the percent improvement in pain from baseline for Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two instances), and placebo. The x-axis shows percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved, demonstrating comparative efficacy of the treatments versus placebo.*

FDA Label Image

Fig 7 (Beae9b9a D630 463b Ae93 F3da73c7049e 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 years with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12. The graph compares pain improvement percentages from baseline between Duloxetine 60 mg once daily and placebo groups, with Duloxetine showing higher percentages of patient improvement across all levels.*

FDA Label Image

Figure 8 (Beae9b9a D630 463b Ae93 F3da73c7049e 09)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily compared to placebo. The x-axis represents percent improvement in pain from 0 to 100%, the y-axis represents percentage of patients improved from 0 to 100%. Two lines show that Duloxetine treatment generally results in higher patient improvement percentages than placebo across various pain improvement thresholds.*

FDA Label Image

Figure 9 (Beae9b9a D630 463b Ae93 F3da73c7049e 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement in pain from >0 to 100, and the y-axis shows the percentage of patients improved, with data points connected for Duloxetine and placebo groups.*

FDA Label Image

Figure 10 (Beae9b9a D630 463b Ae93 F3da73c7049e 11)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for placebo and Duloxetine at 60/120 mg once daily. The graph shows two curves plotting patient improvement percentages across various pain improvement thresholds.*

FDA Label Image

Label Image (Lbl500906775)

Duloxetine 60 mg delayed-release capsules in a carton label from A-S Medication Solutions. The label states each capsule contains 67.3 mg duloxetine hydrochloride equivalent to 60 mg duloxetine, with a package size of 30 capsules. Storage instructions specify to keep at 77 degrees F. The label also includes the product NDC 50090-6775 and manufacturer address in Libertyville, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.